- Revenue increased 9.5% over prior year quarter, in constant currency
- Upper extremity constant currency revenue growth of 11.4% led by Aequalis Ascend Flex
- Increases full year revenue and EBITDA guidance
AMSTERDAM, The Netherlands, Aug. 7, 2014 (GLOBE NEWSWIRE) — Tornier N.V. (Nasdaq:TRNX), a global medical device company focused on providing surgical solutions to orthopaedic extremity specialists, reported today its financial results for the second quarter ended June 29, 2014.
Revenue for the second quarter of 2014 was $86.9 million compared to second quarter 2013 revenue of $78.1 million, an increase of 11.2% as reported and 9.5% in constant currency.
Second quarter 2014 revenue of Tornier’s extremities product categories totaled $71.9 million compared to $65.6 million in the same quarter a year ago, an increase of 9.7% as reported and 8.8% in constant currency. Second quarter revenue of the Company’s large joints and other product lines was $14.9 million, an increase of 13.2% in constant currency over the same quarter in 2013.
Dave Mowry, President and Chief Executive Officer of Tornier, commented, “I am pleased with the progress we have continued to make in Phase 2 of our U.S. sales force transition and training. This progress, combined with ongoing adoption of our market leading Aequalis Ascend Flex shoulder system and solid international performance, resulted in strong financial results in the second quarter, including double-digit upper extremities growth.”
The Company’s second quarter 2014 adjusted EBITDA, as defined in the GAAP to non-GAAP reconciliation provided later in this release, was $6.1 million, or 7.0% of reported revenue, compared to $7.3 million, or 9.4% of revenue, in the same quarter of the prior year.
Mr. Mowry added, “Our second quarter EBITDA reflects the ongoing U.S. sales force transition, geographic expansion and new product development activity. We believe these investments will enhance our long-term growth potential. While some risk remains in the transition process, our results through the first half of the year give us more confidence in the execution of Phase 2 and we have increased our full year financial guidance accordingly.”
Second Quarter 2014 Revenue Highlights
Extremities
- Revenue from the upper extremity joints and trauma category was $53.8 million, an increase of 11.4% in constant currency over the same quarter in 2013. This growth was led by the Aequalis Ascend family of shoulder joint replacement products, which continued to gain global surgeon acceptance.
- Revenue from Tornier’s lower extremity joints and trauma category in the second quarter of 2014 was $14.5 million, an increase of 3.7% in constant currency over the prior year quarter. Solid sales growth of the Company’s Salto Talarisankle joint replacement system was offset by lower sales of foot and ankle fixation products, which were impacted by the Company’s U.S. sales transition activities.
- Revenue from the sports medicine and biologics product category was $3.7 million in the second quarter of 2014, a decrease of 5.9% in constant currency over the same quarter in 2013, reflecting a decline in the Company’s soft tissue anchor products.
Large Joints
Constant currency revenue growth for large joints and other products was 13.2% and was led by the Company’s hip products that benefitted from the release of new minimally invasive instrumentation in Europe late in 2013.
Geographic Revenue
Tornier’s international revenue increased 16.7% as reported and 12.8% in constant currency as compared to the second quarter of 2013 and represented 43.8% of reported global revenue. Revenue in the United States increased by 7.2% and represented 56.2% of reported global revenue.
Third Quarter 2014 Outlook
- The Company projects third quarter 2014 constant currency revenue to be in the range of $69 to $73 million, representing constant currency growth of 3.4% to 9.4% over the same period last year.
- Based on recent currency exchange rates, third quarter 2014 reported revenue is projected to be in the range of $70 to $74 million, representing growth of 4.8% to 10.8% over the same period last year.
- Revenue from Tornier’s extremities product categories in the third quarter of 2014 is expected to be in the range of $60 to $63 million, representing constant currency growth of 5.4% to 10.6% over the same period last year.
- The Company projects third quarter 2014 adjusted EBITDA to be in the range of $2 to $4 million, or 2.9% to 5.4% of reported revenue.
Fiscal Year 2014 Outlook
- The Company is increasing full year guidance and now projects 2014 constant currency revenue to be in the range of $328 to $336 million, representing an increase of 5.5% to 8.1% over last year.
- Based on recent currency exchange rates, 2014 reported revenue is projected to be in the range of $331 to $339 million, representing an increase of 6.4% to 9.0% over last year.
- Revenue from Tornier’s extremities product categories in 2014 is expected to be in the range of $273 to $279 million, representing an increase in constant currency of 5.8% to 8.2% over last year.
- The Company projects 2014 adjusted EBITDA to be in the range of $27 to $31 million, or 8.2% to 9.1% of reported revenue.
Conference Call
Tornier will host a conference call today at 4:30 p.m. eastern time to discuss its second quarter 2014 financial results and its outlook for 2014. The conference call will be available to interested parties through a live audio webcast available through the Company’s website at www.tornier.com. Those without internet access may join the call from within the U.S. by dialing (877) 673-5355; outside the U.S., dial (760) 666-3805.
A telephone replay will be available for ten days following the call by dialing (855) 859-2056 for domestic participants and (404) 537-3406 for international participants. When prompted, please enter the replay pin number 69089307. For those who are not available to listen to the live webcast, the call will be archived for one year on Tornier’s website.
Forward-Looking Statements
Statements contained in this release that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations of future events and often can be identified by words such as “expect,” “should,” “project,” “anticipate,” “intend,” “will,” “can,” “may,” “believe,” “could,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning or the use of future dates. Examples of forward-looking statements in this release include Tornier’s financial guidance for the third quarter and full year 2014. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Tornier’s actual results to be materially different than those expressed in or implied by Tornier’s forward-looking statements. For Tornier, such uncertainties and risks include, among others, Tornier’s future operating results and financial performance; Tornier’s reliance on its independent sales agencies and distributors to sell its products and the effect on its business and operating results of agency and distributor changes, transitions to direct selling models in certain geographies and the recent transition of its U.S. sales channel towards focusing separately on upper and lower extremity products; risks associated with Tornier’s acquisition of OrthoHelix and subsequent integration activities; fluctuations in foreign currency exchange rates; the effect of global economic conditions; the European sovereign debt crisis and austerity measures; risks associated with Tornier’s international operations and expansion; the timing of regulatory approvals and introduction of new products; physician acceptance, endorsement, and use of new products; the effect of regulatory actions, changes in and adoption of reimbursement rates and product recalls; competitor activities; Tornier’s manufacturing capacity; Tornier’s leverage and access to credit under its credit agreement; and changes in tax and other legislation. More detailed information on these and other factors that could affect Tornier’s actual results are described in Tornier’s filings with the U.S. Securities and Exchange Commission, including its most recent annual report on Form 10-K for the fiscal year ended December 29, 2013 and subsequent quarterly report on Form 10-Q. Tornier undertakes no obligation to update its forward-looking statements.
About Tornier
Tornier is a global medical device company focused on providing solutions to surgeons who treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot. The Company’s broad offering of over 95 product lines includes joint replacement, trauma, sports medicine, and biologic products to treat the extremities, as well as joint replacement products for the hip and knee in certain international markets. Since its founding approximately 70 years ago, Tornier’s “Specialists
Serving Specialists” philosophy has fostered a tradition of innovation, intense focus on surgeon education, and commitment to advancement of orthopaedic technology stemming from its close collaboration with orthopaedic surgeons and thought leaders throughout the world. For more information regarding Tornier, visit www.tornier.com.
Tornier®, Aequalis®, Aequalis Ascend®, Aequalis Ascend® Flex™ and Salto Talaris®
are trademarks of Tornier N.V and its subsidiaries, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Use of Non-GAAP Financial Measures
To supplement Tornier’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), Tornier uses certain non-GAAP financial measures in this release. Reconciliations of the non-GAAP financial measures used in this release to the most comparable U.S. GAAP measures for the respective periods can be found in tables later in this release immediately following the detail of revenue by geography. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for Tornier’s financial results prepared in accordance with GAAP.
| Tornier N.V. | ||||
| Consolidated Statements of Operations | ||||
| (in thousands, except per share data) | ||||
| Three Months Ended | Six Months Ended | |||
| (unaudited) | (unaudited) | |||
| June 29, 2014 | June 30, 2013 | June 29, 2014 | June 30, 2013 | |
| Revenue | $ 86,850 | $ 78,135 | $ 175,875 | $ 160,820 |
| Cost of goods sold | 21,069 | 20,388 | 43,271 | 42,257 |
| Cost of goods sold – acquisition related | 158 | 1,921 | 420 | 3,676 |
| Gross profit | 65,623 | 55,826 | 132,184 | 114,887 |
| 75.6% | 71.4% | 75.2% | 71.4% | |
| Operating expenses | ||||
| Selling, general and administrative | 62,504 | 51,467 | 121,352 | 103,603 |
| Research and development | 6,068 | 5,543 | 11,790 | 11,725 |
| Amortization of intangible assets | 4,320 | 3,784 | 8,654 | 7,621 |
| Special charges | 686 | 3,408 | 3,372 | 4,927 |
| Total operating expenses | 73,578 | 64,202 | 145,168 | 127,876 |
| Operating loss | (7,955) | (8,376) | (12,984) | (12,989) |
| Other income (expense) | ||||
| Interest income | 40 | 57 | 108 | 96 |
| Interest expense | (1,365) | (2,037) | (2,714) | (4,255) |
| Foreign currency transaction loss | (214) | (705) | (43) | (786) |
| Loss on extinguishment of debt | — | (1,127) | — | (1,127) |
| Other non-operating income | 7 | 71 | 9 | 88 |
| Loss before income taxes | (9,487) | (12,117) | (15,624) | (18,973) |
| Income tax expense | (961) | (420) | (61) | (462) |
| Consolidated net loss | $ (10,448) | $ (12,537) | $ (15,685) | $ (19,435) |
| Net loss per share | ||||
| Basic and diluted | $ (0.21) | $ (0.28) | $ (0.32) | $ (0.45) |
| Weighted average ordinary shares outstanding | ||||
| Basic and diluted | 48,612 | 45,004 | 48,568 | 43,379 |
| Tornier N.V. | ||
| Condensed Consolidated Balance Sheets | ||
| (in thousands) | ||
| June 29, 2014 | December 29, 2013 | |
| (unaudited) | ||
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $ 31,771 | $ 56,784 |
| Accounts receivable, net | 58,644 | 55,555 |
| Inventory, net | 95,560 | 87,011 |
| Deferred income taxes and other current assets | 30,827 | 27,175 |
| Total current assets | 216,802 | 226,525 |
| Instruments, net | 68,943 | 63,055 |
| Property, plant and equipment, net | 44,419 | 43,494 |
| Goodwill and intangibles, net | 361,694 | 369,148 |
| Deferred income taxes and other assets | 2,108 | 3,204 |
| Total assets | $ 693,966 | $ 705,426 |
| Liabilities and shareholders’ equity | ||
| Current liabilities | ||
| Short-term borrowing and current portion of long-term debt | $ 1,364 | $ 1,438 |
| Accounts payable | 21,149 | 17,326 |
| Accrued liabilities, deferred income taxes and other current liabilities | 63,155 | 57,552 |
| Total current liabilities | 85,668 | 76,316 |
| Other long-term debt | 67,948 | 67,643 |
| Deferred income taxes and other long-term liabilities | 29,038 | 35,659 |
| Total liabilities | 182,654 | 179,618 |
| Shareholders’ equity | 511,312 | 525,808 |
| Total liabilities and shareholders’ equity | $ 693,966 | $ 705,426 |
| Tornier N.V. | ||||
| Consolidated Statements of Cash Flow | ||||
| (in thousands) | ||||
| Three Months Ended | Six months ended | |||
| (unaudited) | (unaudited) | |||
| June 29, 2014 | June 30, 2013 | June 29, 2014 | June 30, 2013 | |
| Cash flows from operating activities | ||||
| Consolidated net loss | $ (10,448) | (12,537) | $ (15,685) | $ (19,435) |
| Adjustments to reconcile consolidated net loss to net cash provided by (used in) operating activities | ||||
| Depreciation and amortization | 10,439 | 8,950 | 20,262 | 17,781 |
| Non-cash foreign currency loss | 210 | 705 | 39 | 786 |
| Deferred income taxes | (1,410) | 576 | (2,581) | 1,788 |
| Share-based compensation | 2,741 | 1,436 | 4,521 | 3,069 |
| Non-cash interest expense and discount amortization | 141 | 277 | 354 | 566 |
| Inventory obsolescence | 2,492 | 1,819 | 5,678 | 4,179 |
| Loss on extinguishment of debt | — | 1,127 | — | 1,127 |
| Inventory step up from acquisition | 158 | 1,921 | 420 | 3,676 |
| Other non-cash items affecting earnings | 244 | 88 | 326 | 1,306 |
| Changes in operating assets and liabilities | ||||
| Accounts receivable | 1,285 | 2,956 | (3,219) | 1,345 |
| Inventories | (7,894) | (912) | (15,326) | (2,060) |
| Accounts payable and accruals | 557 | (3,251) | 8,167 | 5,546 |
| Other current assets and liabilities | (3,069) | (859) | (3,347) | (2,061) |
| Other non-current assets and liabilities | 1,292 | (973) | 496 | 128 |
| Net cash (used in) provided by operating activities | (3,262) | 1,323 | 105 | 17,741 |
| Cash flows from investing activities | ||||
| Acquisition-related cash payments | (5,622) | (3,091) | (7,622) | (6,123) |
| Additions of instruments | (7,735) | (7,571) | (14,535) | (12,450) |
| Purchases of property, plant and equipment | (3,116) | (1,949) | (4,880) | (4,778) |
| Net cash (used in) investing activities | (16,473) | (12,611) | (27,037) | (23,351) |
| Cash flows from financing activities | ||||
| Change in short-term debt | — | (1,000) | — | (1,000) |
| Repayments of long-term debt | (189) | (50,950) | (563) | (53,329) |
| Proceeds from issuance of long-term debt | 477 | — | 477 | — |
| Deferred financing costs | — | (1) | — | (53) |
| Issuance of ordinary shares | 1,845 | 85,614 | 2,196 | 88,256 |
| Net cash provided by financing activities | 2,133 | 33,663 | 2,110 | 33,874 |
| Effect of currency exchange rates on cash and cash equivalents | (40) | 495 | (191) | (657) |
| (Decrease) Increase in cash and cash equivalents | (17,642) | 22,870 | (25,013) | 27,607 |
| Cash and cash equivalents at beginning of period | 49,413 | 35,845 | 56,784 | 31,108 |
| Cash and cash equivalents at end of period | $ 31,771 | $ 58,715 | $ 31,771 | $ 58,715 |
| Tornier N.V. | ||||||
| Selected Revenue Information | ||||||
| (in thousands) | ||||||
| Three Months Ended | Six Months Ended | |||||
| (unaudited) | (unaudited) | |||||
| Percent | Percent | |||||
| June 29, 2014 | June 30, 2013 | change | June 29, 2014 | June 30, 2013 | change | |
| Revenue by product category | ||||||
| Upper extremity joints and trauma | $ 53,826 | $ 47,846 | 12.5% | $ 106,881 | $ 95,965 | 11.4% |
| Lower extremity joints and trauma | 14,469 | 13,911 | 4.0% | 29,542 | 28,984 | 1.9% |
| Sports medicine and biologics | 3,653 | 3,823 | -4.4% | 7,540 | 7,934 | -5.0% |
| Total extremities | 71,948 | 65,580 | 9.7% | 143,963 | 132,883 | 8.3% |
| Large joints and other | 14,902 | 12,555 | 18.7% | 31,912 | 27,937 | 14.2% |
| Total | $ 86,850 | $ 78,135 | 11.2% | $ 175,875 | $ 160,820 | 9.4% |
| Revenue by geography | ||||||
| United States | $ 48,848 | $ 45,579 | 7.2% | $ 98,813 | $ 93,567 | 5.6% |
| International | 38,002 | 32,556 | 16.7% | 77,062 | 67,253 | 14.6% |
| Total | $ 86,850 | $ 78,135 | 11.2% | $ 175,875 | $ 160,820 | 9.4% |
| Tornier N.V. | |||||
| Reconciliation of Revenue to Non-GAAP Revenue on a Constant Currency Basis | |||||
| (in thousands) | |||||
| Three Months Ended | |||||
| (unaudited) | |||||
| June 29, 2014 | June 30, 2013 | ||||
| Foreign | Percent | ||||
| exchange | change on | ||||
| impact as | Revenue on a | a constant | |||
| Revenue as | compared to | constant | Revenue as | currency | |
| reported | prior period | currency basis | reported | basis | |
| Revenue by product category | |||||
| Upper extremity joints and trauma | $ 53,826 | $ (509) | $ 53,317 | $ 47,846 | 11.4% |
| Lower extremity joints and trauma | 14,469 | (40) | 14,429 | 13,911 | 3.7% |
| Sports medicine and biologics | 3,653 | (57) | 3,596 | 3,823 | -5.9% |
| Total extremities | 71,948 | (606) | 71,342 | 65,580 | 8.8% |
| Large joints and other | 14,902 | (686) | 14,216 | 12,555 | 13.2% |
| Total | $ 86,850 | $ (1,292) | $ 85,558 | $ 78,135 | 9.5% |
| Revenue by geography | |||||
| United States | $ 48,848 | $ — | $ 48,848 | $ 45,579 | 7.2% |
| International | 38,002 | (1,292) | 36,710 | 32,556 | 12.8% |
| Total | $ 86,850 | $ (1,292) | $ 85,558 | $ 78,135 | 9.5% |
| Six Months Ended | |||||
| (unaudited) | |||||
| June 29, 2014 | June 30, 2013 | ||||
| Foreign | Percent | ||||
| exchange | change | ||||
| impact as | Revenue on a | on a constant | |||
| Revenue as | compared to | constant | Revenue as | currency | |
| reported | prior period | currency basis | reported | basis | |
| Revenue by product category | |||||
| Upper extremity joints and trauma | $ 106,881 | $ (664) | $ 106,217 | $ 95,965 | 10.7% |
| Lower extremity joints and trauma | 29,542 | (16) | 29,526 | 28,984 | 1.9% |
| Sports medicine and biologics | 7,540 | (88) | 7,452 | 7,934 | -6.1% |
| Total extremities | 143,963 | (768) | 143,195 | 132,883 | 7.8% |
| Large joints and other | 31,912 | (1,242) | 30,670 | 27,937 | 9.8% |
| Total | $ 175,875 | $ (2,010) | $ 173,865 | $ 160,820 | 8.1% |
| Revenue by geography | |||||
| United States | $ 98,813 | $ — | $ 98,813 | $ 93,567 | 5.6% |
| International | 77,062 | (2,010) | 75,052 | 67,253 | 11.6% |
| Total | $ 175,875 | $ (2,010) | $ 173,865 | $ 160,820 | 8.1% |
| Tornier N.V. | ||||
| Reconciliation of Net Loss to | ||||
| Non-GAAP Adjusted Earnings Before Interest, Taxes, Depreciation | ||||
| and Amortization (EBITDA) | ||||
| (in thousands) | ||||
| Three Months Ended | Six Months Ended | |||
| (unaudited) | (unaudited) | |||
| June 29, 2014 | June 30, 2013 | June 29, 2014 | June 30, 2013 | |
| Revenue, as reported | $ 86,850 | $ 78,135 | $ 175,875 | $ 160,820 |
| Net loss, as reported | $ (10,448) | $ (12,537) | $ (15,685) | $ (19,435) |
| Interest income | (40) | (57) | (108) | (96) |
| Interest expense | 1,365 | 2,037 | 2,714 | 4,255 |
| Income tax expense | 961 | 420 | 61 | 462 |
| Depreciation | 6,119 | 5,166 | 11,608 | 10,160 |
| Amortization | 4,320 | 3,784 | 8,654 | 7,621 |
| Subtotal Non-GAAP EBITDA | 2,277 | (1,187) | 7,244 | 2,967 |
| Other non-operating (income) | (7) | (71) | (9) | (88) |
| Foreign currency transaction loss | 214 | 705 | 43 | 786 |
| Loss on extinguishment of debt | — | 1,127 | — | 1,127 |
| Share-based compensation | 2,741 | 1,436 | 4,521 | 3,069 |
| Inventory step-up from acquisition | 158 | 1,921 | 420 | 3,676 |
| Special Charges: | ||||
| Acquisition, integration and distribution transition costs | 123 | 2,194 | 2,036 | 3,713 |
| Restructuring | 563 | — | 1,011 | — |
| Legal settlements | — | 1,214 | — | 1,214 |
| Other | — | — | 325 | — |
| Non-GAAP adjusted EBITDA | $ 6,069 | $ 7,339 | $ 15,591 | $ 16,464 |
| Non-GAAP adjusted EBITDA margin | 7.0% | 9.4% | 8.9% | 10.2% |
| Tornier N.V. | ||||
| Reconciliation of Net Loss and Loss per Share | ||||
| to Adjusted Net Loss and Adjusted Net Loss per Share | ||||
| (in thousands, except per share amounts) | ||||
| Three Months Ended | Six Months Ended | |||
| (unaudited) | (unaudited) | |||
| June 29, 2014 | June 30, 2013 | June 29, 2014 | June 30, 2013 | |
| Net loss, as reported | $ (10,448) | $ (12,537) | $ (15,685) | $ (19,435) |
| Inventory step-up from acquisition, net of tax | 153 | 1,904 | 403 | 3,653 |
| Reversal of valuation allowance from acquisition | (146) | — | (146) | (540) |
| Loss on extinguishment of debt | — | 1,127 | — | 1,127 |
| Special charges, net of tax: | ||||
| Acquisition, integration and distribution transition costs | 123 | 2,188 | 1,011 | 3,707 |
| Restructuring | 563 | — | 2,036 | — |
| Legal settlements | — | 1,214 | — | 1,214 |
| Other | — | — | 325 | — |
| Non-GAAP adjusted net loss | (9,755) | (6,104) | (12,381) | (10,274) |
| Net loss per share, as reported | ||||
| Basic and diluted | $ (0.21) | $ (0.28) | $ (0.32) | $ (0.45) |
| Inventory step-up from acquisition, net of tax | — | 0.04 | 0.01 | 0.08 |
| Reversal of valuation allowance from acquisition | (0.00) | — | (0.00) | (0.01) |
| Loss on extinguishment of debt | — | 0.02 | — | 0.02 |
| Special charges, net of tax: | ||||
| Acquisition, integration and distribution transition costs | — | 0.05 | 0.02 | 0.09 |
| Restructuring | 0.01 | — | 0.03 | — |
| Legal settlements | — | 0.03 | — | 0.03 |
| Other | — | — | 0.01 | — |
| Non-GAAP adjusted net loss per share | ||||
| Basic and diluted | $ (0.20) | $ (0.14) | $ (0.25) | $ (0.24) |
| Weighted average ordinary shares outstanding | ||||
| Basic and diluted | 48,612 | 45,004 | 48,568 | 43,379 |
| Tornier N.V. | ||||
| Reconciliation of Net Cash Provided by Operating Activities | ||||
| to Non-GAAP Free Cash Flow | ||||
| (in thousands) | ||||
| Three Months Ended | Six Months Ended | |||
| (unaudited) | (unaudited) | |||
| June 29, 2014 | June 30, 2013 | June 29, 2014 | June 30, 2013 | |
| Net cash (used in) provided by operating activities, as reported | $ (3,262) | $ 1,323 | $ 105 | $ 17,741 |
| Adjusted for: | ||||
| Additions of instruments, as reported | (7,735) | (7,571) | (14,535) | (12,450) |
| Purchases of property, plant and equipment, as reported | (3,116) | (1,949) | (4,880) | (4,778) |
| Non-GAAP adjusted free cash flow | $ (14,113) | $ (8,197) | $ (19,310) | $ 513 |
| Tornier N.V. | ||||
| Reconciliation of Gross Margin and Gross Margin % | ||||
| to Non-GAAP Adjusted Gross Margin and Gross Margin % | ||||
| (in thousands) | ||||
| Three Months Ended | Six months ended | |||
| (unaudited) | (unaudited) | |||
| June 29, 2014 | June 30, 2013 | June 29, 2014 | June 30, 2013 | |
| Revenue, as reported | $ 86,850 | $ 78,135 | $ 175,875 | $ 160,820 |
| Gross margin, as reported | $ 65,623 | $ 55,826 | $ 132,184 | $ 114,887 |
| Gross margin %, as reported | 75.6% | 71.4% | 75.2% | 71.4% |
| Adjusted for: | ||||
| Inventory step-up due to acquisition | 158 | 1,921 | 420 | 3,676 |
| Non-GAAP adjusted gross margins | 65,781 | 57,747 | 132,604 | 118,563 |
| Non-GAAP adjusted gross margin % | 75.7% | 73.9% | 75.4% | 73.7% |
| Tornier N.V. | ||||
| Reconciliation of Operating Expenses to | ||||
| Non-GAAP Adjusted Operating Expenses | ||||
| Three Months Ended | Six months ended | |||
| (unaudited) | (unaudited) | |||
| June 29, 2014 | June 30, 2013 | June 29, 2014 | June 30, 2013 | |
| Revenue, as reported | $ 86,850 | $ 78,135 | $ 175,875 | $ 160,820 |
| Operating Expenses, as reported | 73,578 | 64,202 | 145,168 | 127,876 |
| Operating expenses as a percentage of revenue, as reported | 84.7% | 82.2% | 82.5% | 79.5% |
| Adjusted for: | ||||
| Amortization of intangible assets | (4,320) | (3,784) | (8,654) | (7,621) |
| Special charges | (686) | (3,408) | (3,372) | (4,927) |
| Total adjustments | (5,006) | (7,192) | (12,026) | (12,548) |
| Non-GAAP adjusted operating expenses | $ 68,572 | $ 57,010 | $ 133,142 | $ 115,328 |
| Non-GAAP adjusted operating expenses as a percentage of revenue | 79.0% | 73.0% | 75.7% | 71.7% |
| Tornier N.V. | ||||
| Reconciliation of Projected 2014 Operating Loss | ||||
| to Projected Non-GAAP Adjusted EBITDA | ||||
| (in millions) | ||||
| Three Months Ended | Twelve months ended | |||
| (unaudited) | (unaudited) | |||
| September 29, 2014 | December 29, 2014 | |||
| Low | High | Low | High | |
| Revenue | $ 70.0 | $ 74.0 | $ 331.0 | $ 339.0 |
| Operating Loss | $ (14.1) | $ (10.2) | $ (33.0) | $ (25.2) |
| Adjusted for: | ||||
| Inventory step-up due to acquisition | 0.2 | 0.1 | 0.7 | 0.5 |
| Depreciation and amortization expense | 11.3 | 10.5 | 43.1 | 41.5 |
| Share-based compensation | 2.7 | 2.2 | 10.0 | 8.9 |
| Special charges | 1.9 | 1.4 | 6.2 | 5.3 |
| Total adjustments | $ 16.1 | $ 14.2 | $ 60.0 | $ 56.2 |
| Non-GAAP adjusted EBITDA | $ 2.0 | $ 4.0 | $ 27.0 | $ 31.0 |
| Non-GAAP adjusted EBITDA margin | 2.9% | 5.4% | 8.2% | 9.1% |
Tornier believes the non-GAAP financial measures presented in this release provide additional meaningful information for measuring Tornier’s financial performance and are measures frequently used by Tornier’s management, as well as securities analysts and investors. Tornier uses the non-GAAP financial measures as supplemental measures of its performance and believes such measures facilitate operating performance comparisons from period to period and company to company by factoring out potential differences caused by charges not related to Tornier’s regular, ongoing business, including non-cash charges, certain large and unpredictable charges, acquisitions, dispositions, litigation settlements and tax positions. Tornier’s management uses the non-GAAP financial measures to assess the performance of Tornier’s core operations, analyze underlying trends in Tornier’s businesses, establish operational goals and forecasts, and evaluate Tornier’s performance period over period and in relation to the operating results of its competitors. Tornier’s management uses the non-GAAP financial measures to help allocate its resources to both ongoing and prospective business initiatives and to help make budgeting and spending decisions, for example, between product development expenses, research and development expenses, and selling, general and administrative expenses. Tornier’s management is evaluated on the basis of several of these non-GAAP financial measures when determining achievement of performance incentive compensation goals.
Tornier believes that non-GAAP financial measures have limitations as analytical tools since they do not reflect all of the amounts associated with Tornier’s operating results as determined in accordance with GAAP and should only be used to evaluate Tornier’s operating results in conjunction with the corresponding GAAP measures. Accordingly, revenue on a constant currency basis should not be used as a substitute for revenue, EBITDA, adjusted EBITDA, adjusted net income (loss) and adjusted net income (loss) per share should not be used as a substitute for net income or net income per share; adjusted EBITDA margin should not be used as a substitute for net margin or operating margin; free cash flow should not be used as a substitute for cash flows from operations; adjusted gross margin and gross margin percentage should not be used as a substitute for gross margin or gross margin as a percentage of revenue and adjusted operating expenses and adjusted operating expenses as a percentage of revenue should not be used as a substitute for operating expenses and operating expenses as a percentage of revenue, in each case as determined in accordance with GAAP. Neither EBITDA, adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted net income (loss) per share, free cash flow, adjusted gross margin and gross margin as a percentage of revenue and adjusted operating expenses and adjusted operating expenses as a percentage of revenue, should be an indication of whether cash flow will be sufficient to fund Tornier’s cash requirements. Additionally, the calculation of non-GAAP financial measures is not based on any comprehensive or standard set of accounting rules or principles. Accordingly, Tornier’s definitions of revenue on a constant currency basis, EBITDA, adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted net income (loss) per share, free cash flow, adjusted gross margin and gross margin as a percentage of revenue and adjusted operating expenses and adjusted operating expenses as a percentage of revenue, may differ from the definitions of other companies using the same or similar names limiting, to some extent, the usefulness of such measures for comparison purposes.
For further information regarding why Tornier believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to Tornier’s current report on Form 8-K filed today with the Securities and Exchange Commission which attaches this release as an exhibit. This current report on Form 8-K is available on the SEC’s website at www.sec.gov or on Tornier’s website at www.tornier.com.
CONTACT: Tornier N.V.
Shawn McCormick
Chief Financial Officer
(952) 426-7646
shawn.mccormick@tornier.com
